TFS Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

TFS Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-79,237	Closed	-$1.17M	–	863
2017 Q1	$1.17M	Buy	+79,237	New	+$1.28M	0.38%	50
2016 Q4	–	Sell	-74,144	Closed	-$1.34M	–	980
2016 Q3	$1.34M	Buy	+74,144	New	+$1.45M	0.32%	114
2015 Q2	–	Sell	-21,433	Closed	-$557K	–	1184
2015 Q1	$557K	Buy	+21,433	New	+$393K	0.05%	517
2014 Q3	–	Sell	-121,398	Closed	-$1.92M	–	1320
2014 Q2	$1.92M	Buy	+121,398	New	+$1.73M	0.15%	196
2014 Q1	–	Sell	-69,828	Closed	-$532K	–	1698
2013 Q4	$532K	Buy	+69,828	New	+$377K	0.03%	800

Other funds holding HZNP

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

TFS Capital's HZNP Position: Q2 2017 in Review

TFS Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2017, closing a stake of 79,237 shares — an estimated $1.17M sold.

TFS Capital first reported a position in HZNP in Q4 2013 and held it in 5 quarters. The position peaked at $1.92M in Q2 2014. 190 funds tracked by Wall St. Rank hold HZNP as of Q2 2017.

TFS Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2017 after selling out during the quarter.
TFS Capital sold 79,237 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2017, an estimated $1.17M.
TFS Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 5 quarters.
TFS Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.92M in Q2 2014.
190 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.